Compare SMID & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | MXCT |
|---|---|---|
| Founded | 1960 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 136.0M |
| IPO Year | 1996 | 2021 |
| Metric | SMID | MXCT |
|---|---|---|
| Price | $30.94 | $1.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 11.6K | ★ 974.5K |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $93,446,000.00 | $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $121.12 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.60 | $0.64 |
| 52 Week High | $43.62 | $2.28 |
| Indicator | SMID | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 34.79 |
| Support Level | $28.01 | $0.97 |
| Resistance Level | $31.21 | $1.16 |
| Average True Range (ATR) | 1.11 | 0.09 |
| MACD | 0.19 | -0.04 |
| Stochastic Oscillator | 69.13 | 3.26 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.